Report on the Nutrition and Chronic Diseases Status of Chinese Residents 2020. Acta Nutrimenta Sinica. 2021;42(6):521 (in Chinese).

Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012;308(11):1150–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nasr P, Fredrikson M, Ekstedt M, Kechagias S. The amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease. Liver Int. 2020;40(5):1069–78.

Article  CAS  PubMed  Google Scholar 

Yang M, Chen J, Yue J, He S, Fu J, Qi Y, et al. Liver fat is superior to visceral and pancreatic fat as a risk biomarker of impaired glucose regulation in overweight/obese subjects. Diabetes Obes Metab. 2023;25(3):716–25.

Article  CAS  PubMed  Google Scholar 

Garg SK, Lin F, Kandula N, Ding J, Carr J, Allison M, et al. Ectopic fat depots and coronary artery calcium in south asians compared with other racial/ethnic groups. J Am Heart Assoc. 2016. https://doi.org/10.1161/JAHA.116.004257.

Article  PubMed  PubMed Central  Google Scholar 

Lim U, Ernst T, Buchthal SD, Latch M, Albright CL, Wilkens LR, et al. Asian women have greater abdominal and visceral adiposity than Caucasian women with similar body mass index. Nutr Diabetes. 2011;1(5): e6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nazare JA, Smith JD, Borel AL, Haffner SM, Balkau B, Ross R, et al. Ethnic influences on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and cardiometabolic risk profile: the international study of prediction of intra-abdominal adiposity and its relationship with cardiometabolic risk/intra-abdominal adiposity. Am J Clin Nutr. 2012;96(4):714–26.

Article  CAS  PubMed  Google Scholar 

Zheng R, Li M, Xu M, Lu J, Wang T, Dai M, et al. Chinese adults are more susceptible to effects of overall obesity and fat distribution on cardiometabolic risk factors. J Clin Endocrinol Metab. 2021;106(7):e2775–88.

Article  PubMed  Google Scholar 

Alruwaili H, Dehestani B, le Roux CW. Clinical impact of liraglutide as a treatment of obesity. Clin Pharmacol. 2021;13:53–60.

PubMed  PubMed Central  Google Scholar 

Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet Med. 2005;22(8):1016–23.

Article  CAS  PubMed  Google Scholar 

Nauck MA, Petrie JR, Sesti G, Mannucci E, Courrèges JP, Lindegaard ML, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2016;39(2):231–41.

Article  CAS  PubMed  Google Scholar 

Yu D, Zou M, Pan Q, Song Y, Li M, Zhang X, et al. Effects of liraglutide or lifestyle interventions combined with other antidiabetic drugs on abdominal fat distribution in people with obesity and type 2 diabetes mellitus evaluated by the energy spectrum CT: a prospective randomized controlled study. Front Endocrinol (Lausanne). 2022;13: 951570.

Article  PubMed  Google Scholar 

van Eyk HJ, Paiman EHM, Bizino MB, de Heer P, Geelhoed-Duijvestijn PH, Kharagjitsingh AV, et al. A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients. Cardiovasc Diabetol. 2019;18(1):87.

Article  PubMed  PubMed Central  Google Scholar 

Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, et al. Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes. Cardiovasc Diabetol. 2011;10:109.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Svane MS, Johannesen HH, Hansen AE, Martinussen C, Bojsen-Møller KN, Hansen ML, et al. Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight. Int J Obes (Lond). 2022;46(11):2058–62.

Article  CAS  PubMed  Google Scholar 

Zhou BF. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults–study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci. 2002;15(1):83–96.

PubMed  Google Scholar 

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.

Article  CAS  PubMed  Google Scholar 

Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courrèges JP, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1608–10.

Article  PubMed  Google Scholar 

Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687–99.

Article  CAS  PubMed  Google Scholar 

Kadouh H, Chedid V, Halawi H, Burton DD, Clark MM, Khemani D, et al. GLP-1 Analog modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity. J Clin Endocrinol Metab. 2020;105(5):1552–63.

Article  PubMed  Google Scholar 

Oliveira FCB, Bauer EJ, Ribeiro CM, Pereira SA, Beserra BTS, Wajner SM, et al. Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue. Front Endocrinol (Lausanne). 2021;12: 803363.

Article  PubMed  Google Scholar 

Li CJ, Yu Q, Yu P, Yu TL, Zhang QM, Lu S, et al. Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients. Cardiovasc Diabetol. 2014;13:36.

Article  PubMed  PubMed Central  Google Scholar 

Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840–6.

Article  CAS  PubMed  Google Scholar 

Goossens GH. The metabolic phenotype in obesity: fat mass, body fat distribution, and adipose tissue function. Obes Facts. 2017;10(3):207–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012;126(10):1301–13.

Article  PubMed  Google Scholar 

Tejani S, McCoy C, Ayers CR, Powell-Wiley TM, Després JP, Linge J, et al. Cardiometabolic health outcomes associated with discordant visceral and liver fat phenotypes: insights from the Dallas Heart Study and UK biobank. Mayo Clin Proc. 2022;97(2):225–37.

Article  PubMed  Google Scholar 

Eguchi Y, Kitajima Y, Hyogo H, Takahashi H, Kojima M, Ono M, et al. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res. 2015;45(3):269–78.

Article  CAS  PubMed  Google Scholar 

Pickhardt PJ, Park SH, Hahn L, Lee SG, Bae KT, Yu ES. Specificity of unenhanced CT for non-invasive diagnosis of hepatic steatosis: implications for the investigation of the natural history of incidental steatosis. Eur Radiol. 2012;22(5):1075–82.

Article  PubMed  Google Scholar 

Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889–919.

Article  PubMed  Google Scholar 

Hu HH, Kim HW, Nayak KS, Goran MI. Comparison of fat-water MRI and single-voxel MRS in the assessment of hepatic and pancreatic fat fractions in humans. Obesity (Silver Spring). 2010;18(4):841–7.

Article  PubMed  Google Scholar 

Kuriyama T, Ishibashi C, Kozawa J, Baden MY, Horii T, Niki A, et al. Effects of liraglutide on intrapancreatic fat deposition in patients with type 2 diabetes. Clin Nutr ESPEN. 2024;59:208–13.

Article  PubMed  Google Scholar